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Acronym Definitions 
ALA: 5-aminolevulinic acid 
A.U.: Absorbance Unit 
Ca: Calcium 
CaF2: Calcium Fluoride 
CT: Computer Tomography 
CW: Continuous Wave 
DCFDA: Dichlorofluorescein Diacetate 
DI water: Deionized water 
DMF: Di-methylformaide 
EDC: 1-Ethyl-3-(3-dimethylaminopropyl)-carbodimide 
Er: Erbium 
FDA: U.S. Food and Drug Administration 
FTIR: Fourier Transform Infrared Spectroscopy 
HBSS: Hank’s Balanced Salt Solution 
HPLC: High-performance liquid chromatography 
Hyd: Hydrazine 
KBr: Potassium Bromide 
Ln: Lanthanide 
MTT: Methylthiazol Tetrazolium 
NaYF4: Sodium Yttrium Fluoride 
NaCF3COO: Sodium Trifluoroacetate 
Nd: Neodymium 
NIR: Near Infra-Red 
NOBF4: Nitrosonium tetrafluoroborate 
OA: Oleic Acid 
OAm: Oleyamine 
ODE: Octadecene-1 
OH-: Hydroxide 
PAA: Polyacrylic acid 
PBS: Phosphate Buffer Saline 
PDT: Photodynamic Therapy 
PET: Positron Emission Tomography 
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PpIX: Protoporphyrin IX 
PS: Photosensitizer 
ROS: Reactive Oxygen Species 
TEM: Transmission Electronic Microscopy 
TFA: Trifluoro-acetate 
Tm: Thulium 
UC: Upconversion 
UCNP: Upconversion Nanoparticle 
UV: Ultra Violet 
Y: Yttrium 
Yb3+: Ytterbium 
1O2: Singlet oxygen 
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Chapter 1: Introduction 
 
Cancer is an uncontrolled growth of cells in the human body. It is the second leading 
cause of death in the US, with 1,660,290 new expected cases and about 580,350 expected 
to die in 2013 (American Cancer Society, 2012a) . Cancer has a variety of treatments, and 
the most effective ones are chemotherapy, radiotherapy and surgery, but all of these 
treatments are not ideal in every cancer case, especially in the later stages when metastasis 
occurs. Due to the side effects that cancer treatments have, scientists are always looking to 
improve current treatments and find better alternatives. (American Cancer Society, 2012b)   
Photodynamic Therapy (PDT) with Upconversion Nanoparticles (UCNPs) is a 
treatment that shows significant potential in this field. PDT is a treatment that uses a 
photosensitizing agent. When photosensitizers are exposed to a visible wavelength of light, 
they produce singlet oxygen (1O2) that kills nearby cells; it has been used mostly for skin 
diseases (Dougherty, 1998).  
UCNPs, is a mixture of lanthanide-doped nano-crystals, which emit high energy 
photons and visible light under excitation by near-infrared (NIR) light. Therefore UCNPs 
will act as transducers, absorbing NIR light and converting it to visible light, which is 
essential in PDT to activate the photosensitizer drug and release singlet oxygen to kill 
cancer cells. Using both PDT and UCNPs for cancer treatment showed promising results, 
especially in In-vivo testing (Wang, 2010). 
The UCNPs that have been used with PDT for cancer treatment were excited at 
980nm wavelength, which showed good results (Idris, 2012). Ytterbium (Yb3+) sensitizer 
is the element commonly used for its unalterable excitation band centered at 980nm. 
However, a longer wavelength from the UCNP with NIR causes the exciting light to 
penetrate deeper into the biological tissue. 
 5-aminolevulinic acid (ALA) is currently used clinically in PDT as an FDA 
approved photosensitizer drug. Through heme biosynthesis, ALA has a hydrophilic 
characteristic and selectivity for photosensitizer protoporphyrin IX (PpIX) production in 
cancer cells, and triggers and generates the red-absorbing photosensitizer PpIX. ALA was 
found to be a suitable agent with the UCNPs designed by the team. It is important to note; 
however, ALA usage in PDT requires the emission of red light, which here is converted 
from NIR light by the UCNPs, in order to activate PpIX.   
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Therefore, the aim of this project was to enhance the use of photodynamic therapy 
with nanoparticles by designing UCNPs with different percentages of Yb3+ in their cores, 
which modifies the level of excitation and red emission at 980nm wavelength. The team 
had reproduced 99.5% Yb and 0.5% Tm UCNPs with blue light emission to learn the 
techniques and skills that are needed to create UCNPs, then started producing Calcium 
Fluoride (CaF2) shell with different ratios of Yb% in UCNPs core due to its 
biocompatibility and promoting more red visible light, looking for possible alternative 
designs by comparing the chemical effects of various percentages of Yb3+ used when 
creating the UCNPs.  
With the five alternative designs, which used 20%, 40%, 60%, 80%, and 98% Yb3+ 
contained in CaF2 UCNPs, the team performed a variety of experiments to verify which 
designs would satisfy requirements. Transmission Electron Microscopic (TEM) images 
were obtained in order to check the CaF2 particle sizes and uniformity, then emission 
spectra data were acquired to check its quantitative values of its emission brightness. Also, 
Fourier Transform Infrared Spectroscopy (FTIR) and High-performance liquid 
chromatography (HPLC) were performed to check the completion of ALA-synthesis. In 
addition, cell viability; Methylthiazol Tetrazolium (MTT) Assay was also performed to 
verify toxicity within HeLa cells. Along with toxicity testing, Cellular Reactive Oxygen 
Species Detection Assay using Dichlorofluorescein Diacetate (DCFDA) was performed to 
measure the singlet oxygen production. As the final stage of verification, the team 
performed MTT assay with porcine tissue to check emission penetration. 
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Chapter 2: Literature Review 
 
The aim of this chapter is to explain and describe the basic concepts of 
Photodynamic therapy (PDT), Upconversion Nanoparticles (UCNPs), and the combination 
use of PDT with UCNPs the benefits and drawbacks.  
Photodynamic Therapy (PDT) 
 
 Photodynamic therapy is a non-invasive treatment where involves three main 
components. These components are; the laser with different wavelength, the 
photosensitizer (PS) molecules, and the production of singlet oxygen (Wang, 2013). 
Desired laser with a different wavelength used directly on targeted cells as a source of light, 
this will activate the PS drug causing the production of singlet oxygen, leading to the 
generation of reactive oxygen species (ROS), which is toxic product causing damage to 
cellular components (Sharman, 1999).  
 PDT was used in many clinical trials, the first successful application was recorded 
for curing acne by using ultra-violet (UV) light (Kalka, 2000). For many scientists and 
researchers the achievement using PDT drew attention to the important use in different 
medical fields such as cancer treatment since it was the biggest challenge this day. Cancer 
studies using PDT showed positive results of substituting major cancer therapeutic 
treatment from chemotherapy and radiotherapy with the PDT (Moan, 2003). 
 When the PS absorbs the UV light, the PS goes into a high energy state, transferring 
this energy to the surrounding molecules causing the production of singlet oxygen (1O2) 
or other reactive oxygen species. The ROS species are very toxic and has the ability to 
destroy tumors by either direct cancer cell death by necrosis, apoptosis (Oleinick, 2002), 
or by damaging tumor vasculatures as an anti-angiogenesis effect (Fingar, 1996). 
 The common procedures of PDT treatment starts with injecting drug with the PS in 
a proper delivery system. Once the delivery system spread over a patient’s body, it causes 
drugs to remain at the tumor tissue long period of time than healthy tissues. Then a certain 
laser will be shed upon the area of tumor, which activates PS to release harmful chemicals 
to kill tumor cells as shown in the Figure 1 below. Throughout the excretory system of the 
patient’s body, the gradually clearance of the drug in the body, and the decrease of the 
volume of the tumor will be done (Kalka, 2000). 
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Figure 1. General Schematic of PDT mechanism 
Even though PDT had successful results, it had a poor tissue penetration due to the 
lack of light transmission and severe photo-toxicity (Sharman, 1999). Most PDT PS 
molecules currently used are excited by visible or UV light, which has limited penetration 
depth in biological tissues, therefor this poor tissue penetration will limit the use of PDT 
in treating large or internal tumors (Yang, 2012).   
Upconversion nanoparticles (UCNPs)   
 
 Upconversion Nanoparticles (UCNP) are usually composed with core and shell as 
shown in figure 2 below. Core part of the UCNP, which mostly have a sphere shape, allows 
the process in which the sequential absorption of two or more photons leads to the emission 
of light at shorter wavelength than the excitation wavelength. By properties of the 
composition of core structure, it would have different wavelength of near infra-red (NIR) 
light convertibility and the color of visible light produced. UCNP shell functions to 
affecting to have various intensity of emission and suitable material’s purposes from the 
Core by having the photosensitizers loaded on host matrix of itself. The mechanisms of 
UCNP are accomplished in solid-state materials doped with rare-earth ions, where it 
convert long-wavelength radiation like infrared or near NIR, to a short-wavelength 
radiation (Haase, 2011). 
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Figure 2. Upconversion Nanoparticle Diagram 
 Using lanthanide-doped solids showed high Upconversion efficiencies at a room 
temperature. Upconversion nanoparticles are usually made of host lattices of ceramic 
materials, such as LaF3, YF3, Y2O3, LaPO4, NaYF4 embedded with trivalent lanthanide 
ions like Yb3+, Er3+, and Tm3+ and show a unique phenomenon of absorbing NIR light and 
emitting UV, visible, and NIR light (Xueyuan,2014). The most effective lanthanide (Ln)-
doped UCNP containing host Sodium Yttrium Fluoride (NaYF4) matrix, sensitizer 
Ytterbium (Yb3+) and emitter Thulium (Tm3+) ions (Haase, 2011), where it can absorb NIR 
light from a continuous wave (CW) and emit photons at  shorter wavelengths that extend 
to the UV region (Shen, 2013). When UCNPs excited by the Near-Infrared light it will 
absorb the light and transfer it to the core emitting visible and UV light. 
 In addition, UCNPs show a sharp emission bandwidth, long half-life time, tunable 
emission, high photo-stability, low cytotoxicity, Nano-scale size, visible emission under 
NIR light excitation, greater tissue penetration and the ability for protein attachment as 
well as surface modification used in different biological and clinical applications (Chen, 
2012). Recently, these properties of the UCNPs increases its variety in different usages as 
its purposes (Wang, 2011).  
UCNPs has the potential to be used in many different applications like cell imaging, 
photodynamic therapy, drug delivery and many other applications, since each task is 
different than the other changing the surface molecules for UCNPs is essential procedure 
to make hydrophilic UCNP with pendant functional groups, which will give the ability of 
UCNPs to be used in living organisms. Due to UCNPs’ various types of possible ligand 
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exchanges on the shell surface, ligand engineering involves a ligand exchange reaction 
with hydrophilic bi-functional molecules or involves a direct oxidation of the terminal 
group of native ligands to generate a pendant carboxylic functional group. Ligand attraction 
involves absorption of an additional amphiphilic polymer onto the nanoparticle surface 
through the hydrophobic Van der Waals attraction between the original ligand and 
hydrocarbon chain of the polymer. Surface polymerization involves growing a dense cross-
linked shell on the nanoparticle core by condensation of small monomers. Last but not least 
Layer-by-layer assembly involves electrostatic absorption of alternately charged poly-ions 
on the nanoparticles surface. These entire synthetic procedures yield to hydrophilic 
UCNPs, which could have additional functional groups and further bio-conjugation 
capabilities (Wang, 2013). 
As the first use of UCNP’s NIR-to-UV convertibility, Zhang and his team reported 
NIR-to-UV β-NaYF4, 25%Yb3+, 0.3%Tm3+ UCNPs for photo-controllable gene expression 
(Jayakumar, 2012). Photo-caging is any one of several molecular species that can be 
activated by light; they are used especially in biochemistry to attach a molecule to a 
biologically active compound and then study its behavior once activated. Photo-caging 
involves the caging of molecules of interest by a light-sensitive molecule which can then 
be destroyed by light irradiation to make it functional. Various molecules, like proteins, 
peptides, nucleic acids, amino acids, and drugs, have been photo-caged and delivered to 
animal’s cells and photolysis is done in the area of interest, enabling activation of these 
molecules with very high spatial and temporal resolution. Due to the limitation of photo-
activating systems it can be only use in in-vitro applications, because UV light necessary 
for the uncaging process, which is very harmful, besides having a poor tissue penetration 
depth, which made it useless for in vivo and clinical use. 
NIR light has the deepest tissue penetration compared to visible and UV light. It is 
also safe and is expected to cause minimal photo-damage to the biological specimen 
involved Zhang and his team chose to use UCNPs to convert NIR to UV light. Due to the 
thin layers of mesoporous silica and caged DNA/siRNA in the mesopores, delivery of 
higher payload and protection of the nucleic acids from the harsh environment was 
possible. The method that Zhang and his team used has many advantages to improve photo-
caging by increasing the loading efficiency of nucleic acids when compared to chemical 
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crosslinking. The degree of activation reduces with increase in thickness of the tissue but 
significant activation more than 50% was seen even with a tissue phantom thickness of 0.4 
cm. Data provided by the team showed more efficient loading and delivery of the 
DNA/siRNA cargo molecules. 
The results support the team hypothesis, which showed the necessity of using 
UCNPs for photo-controllable gene expression is that NIR to UV by using UCNPs, which 
can be used for activating photo-caged nucleic acids in deeper tissues compared to 
conventional systems. The results prove that this technique has enormous potential in a 
variety of fields such as gene therapy and specific gene delivery or knockdown. 
Combination of PDT & UCNPs  
 
PDT based on UCNPs has a major advantage of targeting and treating such a deadly 
disease as cancer.  UCNP is the process of converting two or more low energy photons to 
higher output photons. UCNPs have several properties useful in PDT due to its emission 
ability upon a low level of excitation in the NIR of the spectral region including sharp 
emission bandwidth, long lifetime, tunable, high photo-stability as well as lower 
cytotoxicity.  Upon UCNP excitation using NIR light converting longer wavelength into 
emission at a shorter wavelength in UV, visible or, NIR light, which can activate loaded 
photosensitizers molecules to produce singlet oxygen killing cancer cells that is more 
specific to a nanometer regime with minimal photo damage and a significant enhancement 
in light penetration depth. 
Coated NaYF4 UCNP with mesoporous silica were irradiated using a 980nm laser 
causing the loaded drug to release singlet oxygen (1O2). The 1O2 is known for its toxicity 
to targeted cells such as cancer cells. After evaluating the efficiency of the UCNP as a PDT 
agents in in vitro by minimizing the volume of cancer cells caused by the toxicity of 1O2, 
Idris and his lab proceeded an In-vivo experiments (Idris, 2012). Melanoma cell coated 
UCNP injection subcutaneously to mice in four different conditions; UCNP loaded with 
drug then irradiated with a 980nm laser, UCNP loaded with drug, no drug with a laser 
exposure of 980nm, and untreated. After two weeks, cells except UCNP loaded with drug 
then irradiated with a 980nm laser condition formed a solid tumor while cells in group 1 
has considerably been decreased. Current UCNP based PDT application achieved data 
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success, but this process is still limited due to insufficient upconverting efficiency of the 
nanoparticles.  
5-Aminolevulinic acid 
 As discussed in Chapter one, PDT is based on three important elements; light, 1O2 
and a photosensitizer. Photosensitizer is a very important for photosensitization efficacy 
and producing 1O2. Once light gets absorbed, it causes excitation of molecules, which 
activates the photosensitizer (Tian, 2013). PDT can be a new approach of using an 
endogenous photosensitizer protoporphyrin IX (PpIX). PpIX is known as the precursor of 
prophyrins, which are naturally occurring organic compound. One of the most known 
prophyrins is heme; the co-factor of the protein hemoglobin. PpIX is an excellent 
photosensitizer due to its minimum to no photodynamic damage. 
 5-aminolevulinic acid (ALA) is one of the two FDA approved photosensitizers and 
clinically used. When ALA is administrated, it acts as a prodrug. ALA synthesis occurs in 
the mitochondria formed by the condensation of glycine and succinyl CoA, catalyzed by 
ALA-synthase. ALA undergoes several synthetic steps after it is transported into the 
cytosol. The transportation of cytosol causes the production of proto-prophyrins, then 
precursor prophyrinogens, protoporphyrin IX and then heme. As the final stages of heme 
biosynthesis, co-proporphyrinogen gets transported from the cytosol into the mitochondria 
and there converted to prophyrin and PpIX with an iron inserted (Huang, 2005).  
 ALA is an appropriate solution for cancer therapy because of its specificity for 
cancer cells. When ALA administrated exogenously, it acts as a prodrug generating 
photosensitizer PpIX via heme biosynthesis pathway in the cancer cells. The ALA-PDT 
depends on the generation of PpIX, which is the intermediate of heme biosynthesis and 
does not accumulate in the pathway. Generating more PpIX quantities required; therefore, 
ALA administrated exogenously with an active heme biosynthesis, the pathway becomes 
temporarily overloaded. The control mechanism is bypassed, and downstream metabolites 
are synthesized in excess. Next, the ferrochlelatase; catalyze in the biosynthesis of heme 
where it is convert pro proporphyrin IX into heme with insertion of iron. PpIX accumulate 
in the cells because of the low physiologic rate of iron insertion by ferrochelatase, which 
is unable to compensate for the excess PpIX formed and render them photosensitive (Peng, 
1997). 
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 Following, the synthesis of 5-ALA induced in mitochondria, the PpIX selectively 
accumulate in mitochondria causing the death of cells after PDT treatment. ALA has 
excellent intestinal absorption when administrated orally. ALA uses the intestinal and renal 
apical peptide transporters to enter epithelial cells and in some cells ALA is transported 
using system Beta transporters. 
 There are various theories explaining why ALA has a tendency to accumulate in 
tumors and other lesions. ALA tumor accumulation could be caused due to the low level 
of ferrochelatase in comparison with normal cells where less PpIX covered to heme, plus 
tumors have a low pH causing more PpIX retention leading to PpIX accumulation 
(Collaud, 2004). 
 
Figure 3. Schematic of the ALA-UCNPs Entering the Cell 
ALA Advantages: 
- Ability to penetrate the abnormal tumor under Stratum Corneum due to its small size 
and solubility  
- ALA-PpIX accumulate in cells and not the tumor vasculature 
- Rapidly cleared from the system 1-2 days 
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- Easily synthesized  
- ALA- PDT is noninvasive treatment, where it does not harm surrounding tissue  
- ALA can be administrated topically 
ALA disadvantages: 
- ALA has low lipid solubility, therefore has a limited ability crossing biological barriers 
- PpIX limited tissue penetration 1mm 
- ALA stable is an acid environment, pH low as 2-2.5.  
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Chapter 3: Project Strategy 
 
 In this chapter, each planned procedures prioritized by the various objectives and 
constraints will be introduced. The project approach section will also explain the project 
framework of necessary steps to complete the proposed Upconversion Nanoparticle 
(UCNP) Synthesis. 
Initial Client statement 
 
The following initial client statement was given from the client, Dr. Gang Han from 
University of Massachusetts Medical School. 
 
“Photosensitizers are excited by visible or Ultra Violet (UV) light, which has 
limited penetration depth due to the light absorption and scattering by biological 
tissues, resulting in ineffective therapeutic effects to internal or large tumors. 
UCNPs have the ability to convert Near Infra-Red (NIR) light to visible photons, 
which can active photosensitizers adsorbed on nanoparticles via resonance energy 
transfer to generate singlet oxygen (1O2) to kill cancer cells. It would provide an 
alternative to overcome hurdles of current photodynamic therapies. The goal of this 
project is to improve current UCNPs at a single excitation wavelength between 
600nm and 1,200nm created by continuous-wave (CW) laser in order to perform 
better at imaging and safer to use with photodynamic therapy in living organisms.”  
 
 Therefore, more research about photodynamic therapy (PDT) and UCNP has been 
performed. Then, the team arranged meetings and client interviews to better understand 
and clarify the initial client statement. Sets of objectives and constraints were listed to draft   
a revised client statement, which stated the client’s problem and their desired solutions 
more concisely and clearly. 
Objectives 
 
 Through research, the team discovered much information regarding upconversion 
nanoparticles (UCNPs) and Photodynamic Therapy (PDT). With the information, various 
objectives were brought up based on a compiled a list of current problems with UCNPs. 
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After analyzing the client statement, researching UCNP, and scheduling client meetings, 
the following list of objectives were made.  
Objective List 
 
 Particle size 
 Particle uniformity  
 Capable of upconverting NIR light to red visible light 
 Deliver 5-aminolevulinic acid (ALA) to cancer cells 
 
Based on the aforementioned list, an objectives tree was organized. In the objective 
tree, objectives of higher priority such as particle sizes, particle uniformity, capable of 
upconverting NIR light to red visible light, and deliver 5-aminolevulinic acid (ALA) to 
cancer cells were essential requirements of the client’s need. Both particle size and 
uniformity were chosen for their direct relationship with biocompatibility. Either out of the 
given size range or non-uniform shape and size would lose their efficacy and increase 
cytotoxicity in human usage. Also, brighter red visible light transduction will be useful 
since PDT in deeper tissue would have low NIR light power due to the skin penetration. 
Finally, ALA is one of the most important component in PDT due to its role of activating 
photosensitizers to actually kill the cancer cells. Targeted cancer cells, in living organisms, 
bound with UCNPs and later excited with lasers eliminate the issue of 1O2 production. As 
a result, the objectives lay out the critical foundation for the most effective solution. 
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Figure 4. Objective Tree 
All listed objectives were organized into a pair-wise comparison chart to rank 
team’s objectives in order. The objectives of highest priority were compared with other 
objectives of highest priority. Each score of 1, 0.5, and 0 was assigned to objectives of 
high, medium, and low priorities. 
 
Figure 5. Pairwise Comparison Chart 
 As shown in the pairwise comparison chart in figure 5 above, brighter red visible 
light was the most important objective, followed by suitable drug carrier of ALA. While 
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both particle size and uniformity were deemed important, they were considered secondary 
objectives. 
Design Constraints 
 
 Constraints served to determine the real-world effectiveness of designed ideas. 
Failure to meet constraint criteria resulted in an automatic failure of a proposed solution. 
In light of the prior analysis of project requirements and lab research of the boundaries of 
UCNPs as a solution vector, the following list of constraints were made. 
 
 Must have particle size within a range of 20-40nm 
 Must have uniform particle diameter sizes with lower the standard deviation value 
less than 5nm 
 Must transduce the wavelength between 700 to 1,100nm NIR light into visible red 
light more than 1.00×108 absorbance unit (A.U.) 
 Must be proven to be non-toxic through Methylthiazol Tetrazolium (MTT) assay 
 Must reduce cell viability with 12mm thickness of tissue penetration through MTT 
assay  
 Must have stable ALA-conjugation 
 
 In order to have UCNPs fulfill solution scope requirements, the diameter size of the 
particles must consistently be within a range of 20-40nm while responding to lasers emitted 
at a wavelength of 700 to 1,100nm. The design must also demonstrate non-toxicity within 
the body until exposure to controlled activation conditions.  
Functions 
 
 Based on the constraints the team came up with, there were some specific functions, 
which the modified upconversion nanoparticle (UCNP) has to have. After analyzing the 
client statement, researching UCNP, and having a client meeting, the following list of 
functions can be listed. 
 In light of the aforementioned objectives and constraints, a formal list of functions 
that the team's modified UCNPs must have was drafted. 
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 Produce strong red visible light brighter than 1.00×108 A.U. 
 Perform non-toxic activity through cell viability assay 
 Release 1O2 only when it shed with a certain NIR laser 
 In order to utilize UCNPs for the treatment of cancer under the tissue, it needed to 
transduce NIR laser into strong red visible light in order to activate the photosensitizer the 
controls the release of toxins to kill cancer cells.    
Revised Client Statement 
 
 Based on the results of all the mentioned objectives, constraints, and functions 
above, a revised client statement was written. This statement helped the team successfully 
propose a promising design as well as identify potential design alternatives. 
 
“The goal of this project is to build upon current UCNP procedures so that it will 
result in a stable and effective method of treatment for subcutaneous cancer through 
increased light penetration and emission for ALA activation with designed 
wavelength excitation between 600nm and 1,200nm.”   
Project Approach 
 
 With the foundation of the project clearly defined, a project approach was then 
drafted to guide the Upconversion Nanoparticle synthesis project. After establishing 
objectives, constraints, and project goal, the next step was careful design. Due to the 
complexity of synthesizing UCNPs, the team familiarized themselves with the production 
procedures. Background research was conducted to fully understand the various chemical 
compounds and their characteristics in chemical reactions. Due to financial limitations in 
acquiring the necessary chemicals, as shown in figure 6 below, each compound candidate 
was carefully and thoughtfully handled in order to minimize chemical utilization while 
maximizing sample result usefulness. Lab equipment and space was provided by 
University of Massachusetts Medical School. 
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Figure 6. Project Cost Breakdown 
Upconversion Nanoparticle Size and its uniformity 
Biocompatibility and biodegradation were the highest priorities for the project. To 
achieve this goal, it was imperative that the diameter of the created UCNPs stay between 
20nm to 40nm. ALA conjugation on UCNPs added another 10nm increase in diameter 
which would place the UCNP at the ideal range of 30nm to 50nm. A diameter less than 
30nm would result in reduced effectiveness as a drug carrier within the human body while 
a diameter higher than 50nm would result in an inability to penetrate tissue and loss of 
biocompatibility. UCNPs designed to have diameters of 26nm (with a standard deviation 
of 2nm) were designed for use in experiments. However, due to the sensitivity of UCNPs, 
differing materials and procedures effected the size and consistency of the UCNP solutions. 
Furthermore, the molar ratio of components and the amount of Sodium Trifluoroacetate 
(NaCF3COO) affected the size of the particles with more NaCF3COO resulting in 
increased diameters and less NaCF3COO resulting in decreased diameters. To maintain 
uniformity within the UCNP solutions, exacting temperature application had to be 
enforced. Transmission Electronic Microscopy (TEM) was then used to gather results, 
which were then statistically analyzed.     
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Transducing near-Infrared into Visible light and Biocompatibility 
 
 Cancer cells are commonly located under the skin at a depth of roughly 12mm or 
even deeper. In order to utilize UCNPs as treatment, a NIR laser of a 980nm wavelength 
proved the best candidate. After successfully penetrating the skin with the NIR laser, the 
UCNP compound must convert the energy into bright red visible light to trigger the 
activation photosensitizer that controls the release of 1O2. The light emitted from the 
UCNPs, upon activation, must be brighter than 1.00x108A.U. Also, compound selection 
requires biocompatibility, which promotes opsonization of reticuloendothelial system. 
Testing 
 
 Utilizing TEM imaging and Emission Spectra analysis, the team rooted out a 
promising final candidate amongst all the proposed designs. In-vitro tests were then 
performed followed by another round of TEM imaging to check for correct ALA 
conjugation of UCNPs to determine the final size and uniformity. Once those two tests 
were completed, a round of Fourier Transform Infrared Spectroscopy (FTIR) was 
performed to verify the stability and conjugation status of the UCNPs. Next, to determine 
whether or not the UNCPs were correctly releasing 1O2, Fluorescence Intensity of Cellular 
Reactive Oxygen Species Detection Assay (DCFDA) was performed. After the 
confirmation of the release of singlet oxygen, the final design with ALA conjugation was 
then injected directly into a cell culture medium for Methylthiazol Tetrazolium (MTT) 
Assay using HeLa cells. 12mm of porcine skin, which was obtained from a grocery market, 
was then used to simulate human skin tissue and determine the effectiveness of the ability 
of the 980nm wavelength laser to penetrate skin tissue. Despite passing through 12mm of 
skin, the 980nm laser was still able to activate the photosensitizers. These experiments 
were then repeated three times for statistical analysis. 
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Chapter 4: Alternative Designs 
Requirements analysis 
As mentioned in background chapter, Upconversion Nanoparticle (UCNP) for the 
usage of photodynamic therapy (PDT) requires having certain functions as FDA-approved 
drug. As the purpose of this project, primary functions such as particle sizes and uniformity, 
emission brightness, and stability of ALA conjugation are fall within the scope. 
Objectives 
 Particle size 
o Diameter between 20 to 40nm 
o With conjugation, diameter range between 30 to 50nm 
 Particle uniformity  
o Uniformity in size and shape 
o UCNP’s steady action in human body 
 Brighter red visible light 
o More than 1.00×108 absorbance unit (A.U.) 
o Overcome reduced NIR light power after tissue penetration 
 Suitable drug carrier of ALA 
o Delivery of ALA conjugation 
o Stable ALA conjugation 
Alternative designs 
In order to properly evaluate the effects of different design components, it was 
critical for the team to perform research on each and every step of the production process. 
As a result, the team was able to identify three main core components that were essential 
for the core of UCNPs. (Wilhelm, Hirsch, Schueucher, Mayr & Wolfbeis, 2012) They are 
Thulium (Tm), Erbium (Er), and Hydroxide (OH-). As a first step, the team produced a 
synthesis of β – 99.5%Yb 0.5%Tm for the core of the nanoparticle. Since Tm Nanoparticles 
have significant blue emission, which is an ideal design to use as ultraviolet (UV) test. 
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99.5% Yb, 0.5% Tm (alpha phase) 
In a 50ml flask, 0.1365g of Sodium Trifluoro-acetate (NaTFA), 1.3 mg of Thulium 
Trifluoro-acetate (TmTFA), and 0.2547g of Ytterbium Trifluoro-acetate (YbTFA) are 
added and mixed with 1.43g of Oleic Acid (OA), 2.53g of Octadecene-1 (ODE), and 1.34g 
of Oleyamine (OAm). By using temperature controller and magnetic stirrer, the flask was 
heat up to 110°C for degasing. With this degasing process, it would promote release of any 
extra and unnecessary gas between molecules and helps its purity and reaction time. During 
this process, bubbles occurred in the fluid and disappeared after couple of minutes. After 
10 minutes of degasing process, the temperature was controlled to 300°C to initiate alpha 
phase of the nanoparticle. This process lasted for 35minutes to fully transform the fluid 
into alpha phase nanoparticles. Ytterbium Trifluoro-acetate (Yb3+TFA) functions as main 
core, TmTFA as activators, and NaTFA as size controller. After the heating process, the 
team let the fluid to be fully cool down as low as 70°C. Then it was centrifuged and all the 
fluid residue were removed. With the centrifuged alpha phase nanoparticles were diluted 
with 10ml of Hexane. Alpha phase nanoparticles can be checked with its particles sizes 
and uniformity by having either Transmission Electron Microscopy (TEM) images, which 
will be explained further below, taken or simple 980nm Laser test. For the 980nm Laser 
test, increasing laser power more than 2 Ampere will show light emission to estimate its 
uniformity and sizes. 
Transmission Electron Microscopy 
Transmission Electron Microscopy (TEM) uses a beam of electrons to transmit 
through a thin nanoparticle specimen. Using the interaction of the electrons, it filters into 
black and white images to show detailed images. Since the average sizes of UCNPs were 
approximately between 15nm to 100nm, TEM was the only microscopy that allowed 
accurate confirmation of particle size. Nanoparticle sample fluids were then placed in 
circular shaped carbon mesh with a diameter of 2mm. The carbon mesh was then inserted 
into the vacuum of the TEM, manipulating controllers to determine the best locations to 
take images. For UCNPs, 160,000× zoom was recommended to get an image for the 
particle comparison.   
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99.5% Yb, 0.5% Tm (beta phase) 
Once the alpha phase of the nanoparticle production was complete, the team moved 
onto the beta phase. Once all the hexane was dried, 0.1365g of NaTFA was added to the 
flask. Then, a solvent of 2.83g of OA and 2.53g of ODE were added. An ultrasonic bath 
diluted both the NaTFA and the dried alpha phase particles. The degassing process utilized 
in the alpha stage was repeated for 10minutes. Afterwards, the temperature of the solution 
was set to 325°C for 30minutes in order to properly transform the Beta cores. To obtain 
the pure beta phase nanoparticles, the centrifugation and dilution with hexane steps from 
alpha stage were repeated. TEM imagery was then repeated to verify uniformity and size 
as well as the 980nm laser test with 0.5amperes. The 10ml of beta phase core nanoparticles 
were then diluted in hexane. The team transferred half of the nanoparticles (5ml) into a 
50ml flask. Once the solution was fully dried of all hexane, the pure core nanoparticles 
were then mixed with 10% Yb, and 90%Y with 0.068g of NaTFA. 2.83g of OA and 2.53g 
of ODE were also added to function as solvents. The flask was then heated first to 110°C 
for 10min for degasing and then heated to 325°C for 30min, similar to the heating process 
in the beta phase production of the cores. Both Centrifugation and dilution of hexane were 
performed identically to the beta phase core production. After the transfer of the UCNPs 
into hexane into a 20ml glass vial, TEM imagery and 800nm wavelength laser tests were 
conducted as shown in figure 7 below. 
 
Figure 7. 99.5%Yb 0.5%Tm Core nanoparticle with laser and TEM imaging 
These procedures including both alpha and beta phases are considered as the basic 
preparation for producing UCNPs. Having a shell around the beta phase nanoparticle 
causes higher energy transfer and creates brighter emission with different wavelength laser. 
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For example, core nanoparticle already has an emission occurs at 980nm wavelength laser. 
However, Addition of Nd in shell ingredient will make the nanoparticles to be emitted at 
800nm wavelength laser with the same color of emission as the core had originally. 
99.5% Yb, 0.5% Tm (Shell production) 
99.5% Yb and 0.5% Tm with Neodymium (Nd) Shell resulted in significant blue 
emission, which cannot be used for the team’s purpose of this project. Because red 
emission from UCNP will be required to activate photosensitizers, the team had to come 
up with alternative designs of UCNP with biocompatibility and increased red emission. 
 
Figure 8. 99.5%Yb 0.5%Tm Core with NaYF4 shell nanoparticle with laser and TEM imaging 
CaF2 Shell nanoparticles (80%Yb 2%Er core) 
Over the course of research, the team began to consider CaF2 nanoparticles which 
consist of the same compounds as human bone tissue. The nanoparticles also emit red light 
which served as an ideal model to work with the team's planned experiments such as 
penetration tests and imaging.  A CaF2 nanoparticle study showed 80%Yb and 2%Er core 
had the best red emission with fluorescent testing. The team began production of 80%Yb 
and 2%Er CaF2 nanoparticles.  
To produce the CaF2 nanoparticles, the team had to follow a continuous production 
method from alpha phase into shell without the beta phase. 50 ml three neck flasks with 
2.26g of OA and 2.02g of ODE, and 15ml two neck flasks with 5.1mg of Er, 0.068g of 
NaTFA, 0.2050g of YbTA, and 0.385g of YTFA with their solvents of 1.42g of OA and 
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1.27g of ODE were put in the heating plates at 110°C  for the degas process. Prior to the 
10 minutes of degasing process, the team performed ultrasonic bathing for the 15 ml flask 
with solutes in order to fully dilute. After the degas, 50 ml three neck flasks were heated 
up to 310°C, in order to  activate the forming alpha phase process. The success of the 
process was confirmed by the change of color from clear to yellow. Then with 5ml syringe, 
the team transferred all of the degased fluid from the 15ml flask to 50ml flask with its 
temperature of 310°C to start the alpha phase. During the transfer process, the fluid was 
slowly and continuously injected into the 50ml flask over the duration of 5minutes. After 
completing the transfer, the combination of two fluids was kept at a temperature of 310°C 
for an hour. While they were forming alpha phase nanoparticles, the team prepared a 
mixture of 0.5320g of Calcium Trifluoro-acetate (CaTFA) as solutes and 1.42g of OA and 
1.27g of ODE as solvents for the CaF2 shell production. The fluid went through the 
degasing process at 110°C twice with Argon injection in-between the two processes.  
After one hour of alpha phase nanoparticle production, half of the CaF2 shell fluid, 
approximately 1.5ml, was transferred into 50 ml three neck flask with its same method the 
team took as previous fluid transfer with a syringe. Transferring 1.5ml of the fluid at a 
continuous speed for 3minutes activated shell production around the alpha phase 
nanoparticles. After 30minutes of shell production at a consistent temperature of 310°C, 
the second half of the fluid from 15ml flask was transferred into 50ml three neck flask in 
order to promote the stability of the shell. The purpose of separating shell fluid injection 
into two different steps was to increase the chemical bonding structure of shell to be more 
stable and evenly spread around all the alpha phase nanoparticles. 30minutes after the 
second injection, the team removed the heating plate and fully cooled down the fluid to as 
low as 70°C. After the cooling process was complete, the fluid was transferred into a 50 
ml conical centrifuge tube and centrifuged at 7,000rev/min for 10minutes and all fluid 
residues was removed. The centrifuged alpha phase nanoparticles were then diluted with 
10ml of Hexane. TEM imagery and a 980nm laser test were conducted to determine particle 
uniformity and size. The team confirmed the red emission of the UCNPs, which aligned 
well with the planned experiments. In order to confirm with the CaF2 study of 80%Yb 
2%Er, the team produced each different ratio of particles as shown in figure 9. 
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Figure 9. Alternative designs; CaF2 nanoparticles comparison with different ratio of Yb; 20%, 40%, 60%, 80%, and 
98% respectively 
As a result, TEM Images showed different molecule structure as Tm activated 
cores. As previously showed in figure 7 and 8, Tm Cores and shells had a uniformed 
circular shape of particles. However, CaF2 shell particles had very distinctive square shapes 
in figure 10 below. Each particle sizes fell under the given size range of 20 to 40nm as 
stated in objectives. 20%, 40%, 60%, 80%, and 98% Yb composed alternative designs had 
average diameter size of 26, 25, 26, 26, and 28nm respectively. 
 
Figure 10. TEM image of CaF2 nanoparticle with 80%Yb 2%Er 
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After confirming nanoparticles’ size and uniformity with TEM images, the team 
proceeded to move on the experimental processes with CaF2 nanoparticle with 80%Yb 
2%Er. 
ALA Coupling 
 With the advantage of nanotechnology, the team combined ALA-PDT by 
developing upconversion nanoparticles (UCNPs), which were excited by near infrared 
light (NIR) and emitting multicolor to ultraviolet. In this case, the red right needed to 
activate PpIX carried by the UCNP providing better deep tissue penetration. 
 In chapter 4 mentioned how the team developed α-NaYF4:Yb,Er with a 
biocompatible CaF2 shell for imaging applications. Being a component of ossified tissues, 
CaF2 is even more compatible than the conventional NaYF4 shell on UCNPs. The team 
had amplified the red emission of NaYF4:Yb,Er@CaF2 by adjusting the ratio of the core 
Yb3+. 
 Emission spectra under CW 980nm 1 W/cm3 excitation was obtained and 
corresponding photographs of these UCNPs demonstrated chapter 4, it was discovered α-
NaYF4:80%Yb,2%Er@CaF2 had the optimal red emission with 980nm light excitation 
required for the PpIX to produce singlet oxygen and induce tumor death, as seen in-vitro 
with simulated deep-tissue conditions. 
 The team conjugated 5-ALA to the UCNPs by using covalent hydrazine linkage to 
avoid pre-leakage of the ALA that would increase the success of the therapy by increasing 
its bioavailability in figure19 demonstrate the process of conjugating ALA-on 
αNaYF4:80%Yb,2%Er@CaF2.  
Using a 4ml vial, 1ml of α-NaYF4:80%Yb,2%Er@CaF2, 4ml hexane, 5ml 
dimethylformaide (DMF) and 2g of Nitrosonium tetrafluoroborate (NOBF4) were added 
and mixed for 24h using a magnetic stirrer. After 24 hours took the vial contents are poured 
into conical tube, then the vial was washed with a total of 10ml isopropanol ensuring no 
particles are left behind. Using the counter top centrifuge the conical vial was balanced and 
centrifuged for 10min at 7000rpm. After 10min supernatant decanted and small pellet 
formed. The vial contained the pellet-dissolved in10ml of the DMF using sonicator, and 
then added to 30ml single neck flask and 10mg/ml (100mg) of polyacrylic acid (PAA). The 
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flask was placed in an oil tube resting on a temperature/ stirrer controller, temperature set 
on 80oC using a 1000rpm for another 24 hours. 
 The contents, after 24 hours, are poured into conical tube, washed the single neck 
flask with a total of 30ml hexane and 30ml isopropanol and transferred into the same vial. 
The vial was then centrifuged-using 11,000rpm for 30min at temperature of 20oC. The 
pellet formed was dissolved in 10ml deionized water and centrifuged-using 11,000rpm for 
30 minutes and 20oC, this step was repeated twice by the third centrifuge, the pellet re-
solubilized in 5ml phosphate buffer saline (PBS) and centrifuged using the same settings 
previously, this step was repeated twice eliminating the pellet from any free PAA.  
 The solution was then transferred into glass vial, where 0.05g 1-Ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (EDC) and 0.025g N-hydroxysulfosuccinimide 
(Sulfo-NHS) is added to the glass vial and left on the stirrer for two hours. The contents 
were transferred into the conical tube and centrifuged using the centrifuge settings above. 
After completing the centrifuge time, the pellet dissolved in 5ml PBS using the sonicator 
later transferred into glass vial and placed under the hood on a stirrer, carefully 5ml of 
hydrazine transferred into the glass vial and closed immediately which left to react for 24 
hours.  
 The final step before conjugating the ALA, using the contents from the previous 
reaction and centrifuged using 11,000rpm, for 30minutes under 20°C temperature, the 
pellet was then solubilized and centrifuged twice in 5ml deionized water using sonicator to 
make absolutely sure there was no free hydrazine on the UCNPs. After the last wash 5ml 
of methanol and acetic acid was added, repeated twice by following the earlier centrifuge 
settings using the usual settings to make sure there was no water and only methanol and 
acetic acid in the solution. The contents were transferred into glass vial covered with 
aluminum with stir bar, added 4ml of ALA and placed on a medium-high speed stirrer for 
48 hours. 
MQP Report                                                                                                                                      34 
 
 
Figure 11. The Process of Conjugating 5-Aminolevulinic acid on αNaYF4:Yb80%Yb,2%Er@CaF2 
 There are two reasons why the ALA-UCNPs are attracted to cancers cells. One, the 
ALA is an amino acid, carbon based and naturally occurring; therefore the body will not 
recognize it as a furan body and reject it. Second, the hydrazine is composed of two amino 
groups and has a positive charge nitrogen. Since the UCNPs-ALA have a charge of -7mv, 
which is less negative than the cells -40mv ALA-UCNPs they are phagocytized by the cell 
and exposed to the low pH of the endosome. This caused the cleavage of the hydrazine 
linkage and the ALA subsequently diffused to the mitochondria causing the overproduction 
of PpIX. Meanwhile, the leftover Hyd-UCNP in the endosome would remain unharmed 
and be activated by the NIR light, leading to the photosensitization of PpIX and death for 
the cell shown in figure 12.  
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Figure 12. Illustration demonstrating the Production of PpIX in the mitochondria 
Using the final chosen nanoparticle α-NaYF4:Yb(80%),Er(2%)@CaF2 conjugated 
with 5-Aminolevulinic acid (ALA), several experiments were performed to determine the 
consistency of the size using the TEM. A fluorometer was utilized to measure the red 
emission of the ALA-UCNPs in both water and hexane, and Fourier Transform Infrared 
Spectroscopy (FTIR) was used to confirm the conjugation of the ALA to the UCNPs via a 
hydrazine linkage. Then Methylthiazol Tetrazolium Assay (MTT) was performed to 
measure the cell viability and cell imaging demonstrating the generation of reactive oxygen 
species (ROS) 
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Chapter 5: Design Verification 
Transmission Electron Microscopy (TEM): 
 Emission spectra under CW 980nm 1W/cm2 excitation and corresponding 
photographs of these Upconversion Nanoparticles (UCNP) demonstrated that as the 
Ytterbium (Yb3+) core-doping ratio increased from 20% to 80% and that the red emission 
increased dramatically in figure 13a-b. Integrated counts between 600 and 700nm indicated 
a 250% percent increase in red emissions from α-NaYF4:20%Yb,2%Er@CaF2 to α-
NaYF4:80%Yb,2%Er@CaF2 shown in figure 13c below. Furthermore, the red emissions 
of α-NaYF4:80%Yb,2%Er@CaF2 was 15 times stronger than that of ß-NaYF4: 
20%Yb,2%Er@NaYF4. 
 
 
Figure 13. Emission spectra (a) under CW 980 nm 1 W/cm2 excitation and photographs (b) of α-
NaYF4:Yb,Er@CaF2 UCNPs with different Yb-levels (c) Integrated counts of red emission of α-NaYF4:Yb,Er@CaF2 
UCNPs with different Yb-levels.   
 TEM images in figure 14a,b,c below showed that the conjugation process formed 
mono-disperse UCNPs in water and the dynamic light scattering determined the 
hydrodynamic size of UCNP with 5-Aminolevulinic Acid (ALA-UCNP) conjugation was 
about 62.66nm which was appropriate for tumor accumulation. 
A B 
C 
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 Additionally, PAA-UCNPs in water exhibited less than 25% quenching in red 
emission from UCNPs in hexane, which indicated that the UCNPs would efficiently play 
the role of NIR-to-Red visible light transducer for the endogenous protoporphyrin IX 
(PpIX) shown in figure 14d,e below. 
 
Figure 14. Characterization of hydrophilic UCNPs: TEM images of PAA-UCNPs (a), Hyd-UCNPs (b), ALA-UCNPs (c). 
Emission spectra of hydrophilic PAA-UCNPs in distilled water and hydrophobic OA-UCNPs in hexane, both at 
10mg/mL (e) and integrated counts of their red emission indicating about 30% quenching. 
Fourier Transform Infrared Spectroscopy (FTIR) Spectral Analysis 
 FTIR spectral analysis was employed to confirm the conjugation of ALA to the 
UCNPs via a hydrazine linkage. Using an agate mortar and pestle, a 3mg of each sample 
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PAA-UCNPs, Hyd-PAA-UCNPs and ALA-Hyd-PAA-UCNPs were obtained and 
individually grinded with 100mg potassium bromide (KBr) until they formed a fine 
powder. Each sample was then transferred to the center of the filter paper, where a circle 
shape was cut-off and leveled equally filling the entire circle. O-rings were placed on the 
top where the pellet was pressed. Pressure was released after 3 minutes and then the disk 
was carefully removed from the mold as shown in figure 15a,b,c.  
 
Figure 15. Images of the FTIR Process 
On the spectrum for PAA-UCNPs, the peak at 1636cm-1 was attributed to the 
resonance of the carboxyl groups. However, this peak disappeared after its amidation with 
hydrazine, as two new peaks at 1550 and 1408cm-1 arose. These were attributed to the N—
H bending and stretching vibrations of NH3+ respectively. Finally, when the hydrazine 
linkage to ALA was constructed, the peak at 1628cm-1 represents the —N=C— bond 
between the hydrazine-functionalized UCNPs and the ALA and the retention of the peak 
at 1550 cm-1 indicated the full acid-sensitive covalent linkage was successfully constructed 
between the ALA and the UCNPs in figure 16. 
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Figure 16. Full FTIR spectra (A) and partial detailed spectra (B) of PAA-, Hyd-, and ALA-UCNPs. 
High-Performance Liquid Chromatography (HPLC) Analysis: 
 To determine the loading efficiency After the ALA-conjugation process and 
centrifugation of fresh ALA-UCNPs, the methanol-based supernatant was saved and 
vacuum dried and leftover solutes (including un-conjugated ALA) were re-dispersed in 
2mL deionized (DI) water. This solution was evaluated with HPLC to determine the 
concentration of free ALA by a standard curve (264 nm detection wavelength) 
Table 1. Concentration Calculation 
 1 M pure ALA 80% 
Retention Time 1.89 m 1.93 m 
264 nm 5174.89 1453.84 
210 nm 10875.09 2846.25 
Average concentration calculated based on two-wavelength detection: 
80% sample ALA concentration: 0.28 M. 
Methylthiazol Tetrazolium (MTT) Assay: 
 To validate the therapeutic potential of the ALA-conjugated UCNPs, an MTT cell 
proliferation assay was implemented in which HeLa cells were exposed to ALA-UCNPs 
and various controls (all 100µg/mL) for 4 hours followed by irradiation of continuous wave 
(CW) 980 nm light at 1 W/cm2. 
 A 96-well microtiter plate seeded with 1x104 HeLa cells/well was incubated 
overnight at 37ºC with 5% Carbon dioxide (CO2). Cells were subsequently exposed to 
100µg/mL of ALA-UCNPs, Hyd-UCNPs, ALA, or PBS for 4 hours and then irradiated 
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with CW 980nm laser diode at 1W/cm2 for 0, 5, 10, or 20 minutes. After overnight 
incubation, cells were labeled with 12mM solution of MTT in PBS for 4 hours. Finally, the 
media was aspirated and replaced with 50µL DMSO and a plate reader at 540nm 
determined the formazan absorption. 
 Cell viability data as shown in figure 17 have a time-dependent curve for cells 
exposed to ALA-UCNPs, resulting in almost 70% cell killing after 10minutes, while 
controls had minimal cytotoxicity.  
 
 
Figure 17. HeLa cell viability exposed to ALA-UCNPs (100 µg/mL), Hyd-UCNPs (100 µg/mL), free ALA (100 µg/mL), 
and nothing (growth control) and irradiated with CW 980 nm light at 1W/cm2 power density. 
Cell Viability Exposed to 20% and 80% (MTT Assay) 
 
Furthermore, the red-emissions of α- NaYF4:Yb(80%),Er(2%)@CaF2 was 15 
times as strong as that of ß-NaYF4:Yb(20%),Er(2%)@ ß-NaYF4, as shown in figure 13 
the supposed optimal red-emitting UCNP structure. As shown in figure 18, the team 
preformed MTT assay to see the effect of changing in Yb3+ concentration on cell viability 
as shown in figure 18 below. 
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Figure 18. HeLa cell viability exposed to 20% Yb and 80% Yb ALA-UCNPs (100 μg/mL) and 20% Yb and 80% Yb 
Hyd-UCNPs (100 μg/mL) and irradiated with CW 980 nm light at 1W/cm2 power density. 
Singlet Oxygen Detection Cell Imaging 
 
The team validated the production of PpIX and concomitant generation of singlet 
oxygen species caused by exposure to ALA-UCNPs. The team stained cells with 2’, 7’ –
dichlorofluorescein diacetate (DCFDA), a standard fluorescent indicator for singlet oxygen 
generation, and imaged using fluorescence microscopy as shown in figure 19. DCFDA 
diffuses into the cell and is acetylated into a non-fluorescent compound by cellular esterase. 
Reactive oxygen species (ROS) oxidizes it into 2’, 7’ –dichlorofluorescin (DCF), which 
has bright green fluorescence.  
Singlet Oxygen Detection Cell Imaging: Glass-bottom confocal dishes seeded with 
1×106 HeLa cells were incubated overnight at 37ºC with 5% CO2. Cells were subsequently 
exposed to 100μg/mL of ALA-UCNPs or Hyd-UCNPs for 4 hours. Cells were washed 
three times with warmed Hank’s Balanced Salt Solution (HBSS) and then stained with 
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25μM DCFDA in HBSS for 45 minutes. Using a fluorescent microscope equipped with a 
CW 980nm laser diode at 1W/cm2, DCFDA fluorescence was imaged with 495nm 
excitation and 535nm emission between 0, 5, and 10minutes of irradiation using a 60× 
water-immersion objective lens. 
 
Figure 19. Singlet oxygen production detected by fluorescence of DCFDA in HeLa cells exposed to 100 μg/mL of ALA-
UCNPs and irradiated with 0 (a), 5 (b), and 10 (c) minutes of CW 980 nm light at 1W/cm2 power density. Singlet 
oxygen production detected by fluorescence of DCFDA in HeLa cells exposed to 100 μg/mL of Hyd-UCNPs and 
irradiated with 0 (d), 5 (e), and 10 (f) minutes of CW 980 nm light at a 1W/cm2 power density. 
Singlet Oxygen Detection Quantification 
 
Singlet Oxygen Detection Quantification: A 96-well micro-titer plate seeded with 
1×104 HeLa cells/well was incubated overnight at 37ºC with 5% CO2. Cells were 
subsequently exposed to 100μg/mL of ALA-UCNPs, Hyd-UCNPs, ALA, or PBS for 4 
hours and then stained with 25μM DCFDA in HBSS for 45minutes. After irradiation with 
CW 980nm laser diode at 1W/cm2 for 0, 5, or 10 minutes, DCFDA fluorescence was 
immediately determined with a plate reader with 495nm excitation and 535nm emissions. 
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Figure 20. Singlet oxygen quantified by DCFDA fluorescence in HeLa cells exposed to 100μg/mL of ALA UCNPs, Hyd-
UCNPs, ALA, and nothing (growth control). 
MTT Assay with Porcine Tissue 
Once the team achieved effective results using the 80% Yb, PDT was used to 
stimulate in deep tissue. In this regard, pieces of tissue of varying thickness were 
placed between the NIR laser and HeLa cells exposed to UCNPs figure 21a, and 
analyzed for cell viability with an MTT assay figure 21b. Exposure time was 20 
minutes of 980nm irradiation at 1W/cm2 under same condition mentioned in 
previous MTT test. It is also worth noting that with the added distance between the 
meat and cells, the height of the well and the media bathing the cells, the simulated 
depths were greater than the measured thickness of the tissue. 
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Figure 21. Photograph of the setup of simulated visceral tumor conditions in an in vitro MTT assay (a). HeLa cell 
viability exposed to ALA-UCNPs (100 μg/mL) and Hyd-UCNPs (100μg/mL) and irradiated with CW 980nm light at a 
1W/cm2 power density for 20 minutes 
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Chapter 6: Discussion 
Photodynamic Therapy (PDT) with Upconversion Nanoparticles (UCNP) has been 
used in many studies as a potential cancer treatment and showed promising results. As 
such, it has been considered as an alternative treatment for current cancer treatments like 
chemotherapy, radiotherapy and surgery.  However, current techniques are limited by the 
efficiency of the treatment with respect to tissue penetration. This project has demonstrated 
a new technique being studied to increase tissue penetration by increasing red light 
emission through the use of PDT with NaYF4:80%Yb,2%Er@CaF2 UCNPs, which are 
responsible for the activation of the 5-Aminolevulinic Acid (ALA) drug photosensitizer 
(PS). Ytterbium (Yb3+) plays an essential role in changing the amount of red light emission. 
Previous studies showed that 20% Yb3+ produces the best red emission, while the team 
found that 80% Yb3+ gives off the highest red light emission compared to different 
percentages of Yb3+, as figure 21 illustrates. The team confirmed these results through a 
variety of tests that showed the low toxicity of UCNPs, the best red emission intensity by 
using NaYF4:80%Yb,2%Er@CaF2, and the successful and effective ALA conjugation 
which prove that ALA-conjugated UCNPs have therapeutic potential.    
Viability and Effectiveness of UCNPs-ALA for PDT as cancer treatment  
In order to use NaYF4:80%Yb,2%Er@CaF2 UCNPs as an effective activator and 
drug carrier for ALA, the team tested the size of UCNPs, red light emission, the amount of 
ALA conjugation with UCNPs and tested the cell viability. Figure 14 shows results from 
Transmission Electron Microscopy (TEM) imaging that portray the average size of UCNPs 
37nm (Standard Deviation of 3nm) which is in the desired range for physiological testing 
(Xueyuan, 2014). To determine the best red emission intensity that UCNPs are able to 
produce, different percentages of Yb were used to make UCNPs. Figure 13a,b show 
emission spectra under continuous wave (CW) 980nm 1W/cm2 excitation and Yb3+ core-
doping ratio increases 20%, 40, 60, 80, and 98% respectively. 80% Yb3+ produced the 
highest red light emission compared to other percentages. Figure 13c is a photograph of 
the UNCPs emitting. Figure 13 illustrates integrated counts between 600 and 700nm 
indicating that there is a 250% percent increase in red emissions from α-
NaYF4:Yb20%Yb,2%Er@CaF2 to α-NaYF4:Yb80%Yb,2%Er@CaF2, which means that 
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the red light emissions of α- NaYF4:Yb80%Yb,2%Er@CaF2 are 15 times stronger than 
that of ß NaYF4:Yb20%Yb,2%Er@NaYF4.  The importance of red emission is that the PTD 
photosensitizing drug is activated under red emission and in the actual experimental 
process, the team was using the ALA as a photosensitizing drug. 
After the team found that α-NaYF4:Yb80%Yb,2%Er@CaF2 had the optimal red 
emissions, ALA-conjugated α-NaYF4:Yb80%Yb,2%Er@CaF2 were synthesized via the 
process represented in figure 11. In cellular experimentation, the ALA-UCNPs were 
expected to be phagocytized by the cell and exposed to the low pH of the endosome. This 
would cause the cleavage of the hydrazine linkage causing the ALA to diffuse to the 
mitochondria and cause an overproduction of Protoporphyrin IX (PpIX) as shown in figure 
12. During this process the leftover Hyd-UCNP in the endosome would remain unharmed 
within the cells and be activated by the NIR light, leading to the photosensitization of PpIX, 
which will produce singlet oxygen (1O2) and cause the death of the tumor cell. Therefore, 
high red light emission is an important factor in PDT with UCNPs treatment, because red 
light is the excitation light that activates UCNPs which will trigger ALA and activate PpIX. 
The stronger this light is, the deeper its effective distance will be, so it can be used for deep 
cancer treatment.  
After ALA conjugation with UCNPs the team performed various tests to check if 
ALA successfully conjugated to the UCNPs and to verify the amount of ALA that was 
conjugated.  First the team tested if the ALA were successfully conjugated to UCNPs by a 
Fourier transform infrared spectroscopy (FTIR) test and the results demonstrated the 
existence of ALA on UCNP surfaces as shown in figure 16. When the hydrazine linkage 
to ALA was constructed, the peak at 1628cm-1 represents the —N=C— bond between the 
hydrazine-functionalized UCNPs and the ALA and the retention of the peak at 1550cm-1 
indicates that the full acid-sensitive covalent linkage was successfully constructed between 
the ALA and the UCNPs. The second test was High-Performance Liquid Chromatography 
(HPLC), which was used to test the concentration of ALA after ALA conjugation with 
HYD-UCNPs. The results in figure 17 showed that UCNPs 80%Yb-ALA with an ALA 
concentration of 0.28M, exhibited a loading capacity of the ALA is 48.26µmol/10mg in 
the HYD-UCNPs, approximately 50% of the initial amount. 
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After testing the conjugation of ALA with HYD-UCNPs by FTIR and calculating 
the concentration of ALA by HPLC, the team determined that there is a sufficient amount 
of ALA to be used as an effective cancer drug in in-vitro tests, and further, in-vivo testing.  
The team performed Methylthiazol Tetrazolium (MTT) Assay which is used to 
demonstrate multiple facts, firstly to test the toxicity of UCNPs because they will be used 
for human testing and secondly to determine the effectiveness of ALA as a drug to kill 
cancer cells as the team used Hela cells. Figure 17 shows Cell viability data which shows 
that exposing cells to ALA-UCNPs resulted in almost 70% cell death after 10 minutes, 
while UCNPs-HYD showed close similarity to control results, demonstrating that UCNPs 
have low toxicity by themselves and proving that ALA works successfully with UCNPs as 
a cancer treatment. UCNPs were exposed to cells for four hours before the tests were 
performed under CW 980nm 1W/cm2 excitation. 
The team tested the effect of using different Yb3+ concentration on the emission of 
red light as figure 13 demonstrated using 80%Yb3+ increase red light emission 15 time 
more than 20%Yb3+. The team performed MTT assay to see the affect in changing Yb3+ 
concentration on cell viability, as figure 18 shows 80%Yb3+ALA-UCNPs had 70% 
decrease in cell viability while 20%Yb3+ALA-UCNPs had 30% decrease in cell viability, 
the team’s results clearly show that increases in Yb3+ concentration has critical effect on 
cell viability.   
Throughout research, the team found that cells exposed to ALA-UCNPs show 
intensifying DCFDA fluorescence over irradiation time, clearly indicating the production 
of PpIX and then singlet oxygen shown in figure 19 a-c. This data was later corroborated 
with a quantification of the singlet oxygen production by measuring the fluorescence 
intensity of the Cellular Reactive Oxygen Species Detection (DCFDA) using 96-well 
micro-titer plate reader in figure 20. Both DCFDA fluorescence imaging and micro-titer 
plate measurement suggest effective prodrug delivery and subsequent PpIX activation by 
the red emitting UCNPs. 
Finally, once the team had established the optimal red-emission and PDT effect of 
80% Yb3+ UCNPs, simulating PDT in deep-set tumor conditions was desired. After 20 
minutes of irradiation at 1W/cm2, all tissue thicknesses had cell viabilities significant to 
the control (Hyd-UCNPs). While no tissue (0mm) resulted in less than 20% cell viability, 
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6mm had less than 50% cell viability and 12mm had less than 80% cell viability. This 
establishes and validates the feasibility of using UCNPs as a NIR-to-Red visible light 
transducer for prodrug photodynamic therapy at a deep-tissue level (thickness greater than 
1cm). 
Even after ALA conjugation, UCNP size was around 62nm which is still in the 
acceptable range to be used in human testing and appropriate for tumor accumulation, as 
TEM images show in figures 14a,b,c, the conjugation process formed a uniform size and 
distribution of  ALA-UCNPs in water. Since ALA will form an extra layer on the UCNPs 
the team tested emission spectra of UCNPs before and after ALA conjugation and the 
results showed that PAA-UCNPs in water exhibit less than 25% quenching in red emission 
from UCNPs in hexane, indicating the UCNPs are the main factor in NIR-to-Red visible 
light transducer for the endogenous PpIX as shown in figure 14d,e. 
UCNPs for PDT as a cancer Treatment: A larger perspective 
Economics 
It is well known that cancer treatment is one of the most expensive treatments used 
in the medical field. Among the 12 drugs approved by the Food and Drug Administration 
for various cancer conditions in 2012, 11 were priced above $100,000 for a year of 
treatment, and since 2010 the median price has been around $10,000 (Levy, 2013). Despite 
their extreme cost, current cancer drugs do not exhibit high efficiency in the majority of 
cancer cases. If PDT with UCNPs were used as a cancer treatment the team believes that 
it will be less expensive than existing drugs, because the materials that  comprise  UCNPs 
and ALA are not expensive and there is no need for high a quantity of ALA-UCNPs due 
to the highly tumor targeted nature of ALA. 
Societal Influence 
 Environmental effects are very important factor in drug manufacturing, especially 
with the complicated rules and laws that restrict any environmental or pollution effect. It 
is important to understand future effects of the disposals from both the therapy itself and 
also of the materials associated with its manufacturing. The production of UCNPs requires 
the use of lanthanide salts. Yb3+ and Er, current compounds used for doping, show no 
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environmental threat to plants or animals. They are considered biologically lifeless. Water-
soluble compounds of Yttrium (Y) are considered mildly toxic, mostly affecting aquatic 
animals. Therefore waste disposal in the manufacturing process would need to be 
monitored but will not require special licensing or permits to be acquired. (Ytterbium 
Oxide, 2010) (Erbium Oxide, 2008). 
Political Ramification 
Cancer is getting everybody's attention, because cancer is the second cause of death 
in the US (American Cancer Society, 2012a). Any treatment for cancer will have big 
influence on the society because it will change lives and give hope to millions of people 
who are suffering from cancer so searching for affective and successful cancer treatment 
is a need for every person, because there are  a lot of factors are involved in casing  cancer 
like chemical radiation, genetic, tobacco, diet and physical activity and every single person 
living these days are getting exposed to one of these factor which mean everyone is under 
the risk of having cancer. 
Health and Safety 
Safety was a major objective of the design and has been addressed with toxicity 
analyses in-vitro. As for any treatment, the health and safety of the patient is of the highest 
importance. The ultimate goal of PDT with UCNP-ALA would be to kill cancer cells 
without affecting other tissues. The drug is designed to specifically target tumor cells 
without negatively affecting the health of any other organ system, and with minimal side 
effects. 
Ethical Concern 
The main goal of this project is to find alternative cancer treatment for current 
treatment by using PDT with UCNPs-ALA. This would directly improve the lives of all 
patients receiving the treatment and minimal the side effects that occur due to current 
cancer treatments. The ethical concerns that are usually raised are related to marketing, 
administration, and availability of the treatment. During the marketing process it should be 
carefully done so that the expectations of patients do not exceed the limitations of the 
treatment. Patients need to be informed about potency and limitations of the drug, and what 
the treatment does and how it works. Administration of the treatment has to be noninvasive 
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so patient does not have to suffer during treatment. To ensure the level of pain and the 
risks, animal models should be used. Since cancer is a global problem, the treatment needs 
to be made available on multiple continents and would have to be accessible for all 
demographics. Therefore, efforts must be made to keep production costs affordable in the 
international markets. 
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Chapter 7: Final Design and Validation 
As mentioned above, cancer is fatal disease that does not yet have a viable cure. 
There is a pressing need to find an effective preventative treatment. Heretofore, the team 
proposed a design that utilizes Upconversion Nanoparticle conjugated with 5-
aminolevulinic acid (ALA-UCNP) with Photodynamic Therapy (PDT) to treat cancer by 
killing cancer cells in human body. However, producing cancer treatment faces a lot of 
challenges in regards to safety, scalability, efficacy, and specificity.  
 
Figure 22. Schematic of the final design components and its work mechanisms. 
 The goal of this project was to find alternative treatment for cancer by enhancing 
current PDT and making it more effective for cancer therapy, especially for deep cancer. 
The main problem with the current PDT procedure is the penetration depth and, as figure 
22 shows, that the current PDT use 650nm wavelength to activate ALA and produce singlet 
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oxygen. In order to enhance the light penetration and reach deeper tissue, the team used 
UCNPs as transducer which will convert 980nm NIR to red visible light and activate ALA 
to produce singlet oxygen as shown in figure 22. The team successfully synthesized ALA-
UCNPs and found the best red light emission by using 80%Ytterbium (Yb3+). Over the 
course of this project, the team was able to demonstrate hypothetical PDT system with 
various experiments, which showed effective and significant results which strongly make 
PDT with UCNPs as real alternative cancer treatment with great potentials. 
Thus, the specific objectives of this study were to assess the application of novel 
UCNPs as ultraviolet (UV) light emitter to activate ALA is to increase tissue penetration 
by increasing red light emission which was demonstrate by increasing the percentage ratio 
of Yb3+ in UCNPs.  
In order, their priority was determined to evaluate the success of the design: 
1. Specificity 
2. Scalability 
3. Safety    
4. Efficacy 
To make sure that the team’s progress is directed by scientific criteria and as the 
results of simple experiments would guide the parameters chosen for more complex 
procedures. Below, experiments are described in the chronological order in which they 
were performed, with the reasoning for experiment prioritization: 
1. Safety was evaluated first because low cytotoxicity was a constraint for this project; 
the cytotoxic effects of the UCNPs should not compromise cell viability below 90%. 
Therefore, Methylthiazol Tetrazolium (MTT) assay tested the cytotoxicity and it was 
first experiment conducted to ensure that future experiments fell within acceptable 
particle dosages. Following cytotoxicity assays, team test the size of UCNPs to make 
sure they fall in the range of 50nm to 60nm to be used in physiological testing. 
2. Testing the red light emission that produces from UCNPs was next measure test that 
the team conducted in this project, because the main goal of this project is to increase 
the red emission to solve the limitation that current UCNPs have. In effect, data from 
these tests enabled the team to scale the amount of Yb3+ that used in producing UCNPs 
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and at the end chose the best percentage Yb3+ ratio which will help the team maintaining 
maximum design efficiency. 
3. The FTIR and HPLC experiments were performed next, to gauge the efficacy of the 
design by testing if ALA conjugated to UCNPs. Therefore these tests show that UCNPs 
are capable to be used as drug carrier, which would indicate the specificity of the 
delivery system in or design.  
4. To demonstrate the efficacy of the team’s design, MTT assay was utilized if ALA 
working effectively as cancer drug by increment cell death during 980nm wavelength 
laser exposure.  
The cell line chosen to conduct these studies was the HeLa human cervical cancer 
line. All cultures were maintained and prepared using antibiotic-free, DMEM+10% FBS. 
All assays were performed in standard tissue culture polystyrene and incubated at 37oC 
21% Oxygen (O2) and 5% Carbon Dioxide (CO2). All cell counts were determined by 
hemocytometer, without using trypan blue exclusion staining. 
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Chapter 8: Conclusions and Recommendations:  
Conclusions  
The experimental approach showed the possibilities of several features of Calcium 
Fluoride (CaF2) shell Upconversion Nanoparticle’s (UCNP) in vitro activity. After 
considering alternative designs for biocompatibility, one of the biomaterials; CaF2 was 
chosen as the design component. Regarding UCNP’s design selection, Transmission 
Electron Microscopic (TEM) images were used to measure particle size and uniformity for 
each design samples with different percent of Ytterbium (Yb3+) component. Particle sizes 
of 30 to 50nm diameter are allowed for biological usage and met the design objectives. All 
of the samples passed particle size and uniformity requirements in the initials process of 
the experiment series. 
 CaF2-shell UCNPs with 20%, 40%, 60%, 80%, and 98% component of Yb
3+ were 
measured their emission spectra through fluorometer. As a result, CaF2-shell with 80% 
Yb3+ had the strongest red emission, which was approximately about 3.00 × 108 A.U. Using 
the selected alternative design, 5-Aminolevulinic Acid (ALA) and hydrazine conjugation 
was performed for better water solubility and release of singlet oxygen (1O2) to kill target 
cells. Two different conjugated samples were checked for usability through TEM and 
fluorometer tests. The results showed hydrophilic PAA-UCNP were still emitting enough 
brightness, at nearly 3.00×108 A.U. With a uniform particle size of about 40nm. 
 In addition, Fourier Transform Infrared Spectroscopy (FTIR) confirmed the 
conjugating condition of ALA and Hydrazine. Then Methylthiazol Tetrazolium (MTT) 
Assay was preformed to demonstrate that UCNPs having low cytotoxicity, 98% cell 
viability after 10minutes of exposure to 980nm wavelength laser with Hydrazine UCNPs. 
On the other hand, ALA UCNP showed about 30% cell viability on the same MTT assay, 
which proves theory of CaF2 UCNP with ALA Functionality are right. Along with MTT 
Assay, fluorescence intensity images of cells proved about 7 times bigger size of the cells 
were produced of singlet oxygen in the cells. After verified the major photodynamic 
therapy with ALA conjugated UCNP, MTT assay of alternative designs showed CaF2-shell 
UCNP with 80% Yb3+ had the most cell died during 10minutes of 980nm wavelength laser 
exposure. As the last experiment, MTT assay with tissue penetration test resulted less than 
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60% cell viability in 6mm thickness of tissue and less than 80% cell viability with 12mm 
thickness tissue after 10 minutes of exposure of 980nm wavelength laser. 
 This proves that this engineered biocompatible CaF2-shell showed 15-fold 
increment in red emission compared with current one. Also, ALA-conjugation, which was 
a prodrug for red-absorbing photosensitizer protoporphyrin IX (PpIX) to the UCNP, allows 
great control of its release in the cell. In-vitro test of this photodynamic therapy system was 
performed to prove its therapeutic potential such as cell viability of ALA conjugated 
UCNPs and release of toxicity via photosensitizer. 
Recommendations 
 Under the limitation of time scope such as UCNP production, conjugation, and 
experimental process time, this study was limited into partial requirements to become an 
outstanding product for actual pharmaceutical usage. The implementation of following 
recommendations might expand and develop the current characterization of ALA-UCNP 
for cancer treatment. 
1. Repeat experiments in more alternative UCNPs. Due to the delicate process of 
UCNP production, each UCNP sample had slight differences on its size and 
emission. In order to get more accurate and detail data, more sample of UCNP need 
to be tested. 
2. Conduct experiments with in vivo tests. After concluding the project, 
experiments showed promising results of ALA conjugation with CaF2-Shell UCNP 
in PDT. In vivo testing will show great chance of proving its potential in its 
pharmaceutical usage. 
3. Repeat experiments with different laser power. During the course of 
experimental process, 980nm wavelength laser approximately 1W/cm2 power was 
used. Over-heating effects regarding using this laser power with UCNP was rarely 
observed.  
4. Repeat experiments with Zinc-PCA conjugation. Both ALA and Zinc-PCA have 
great function of photosensitizing. Due to the limited research and experiment time, 
the experimental processes were limited into ALA conjugation.  
5. Possible over-heating concerns. Throughout these experiments, the team did not 
discover any significant problem of over-heating effect during the experiments. As 
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the length of the Laser wave gets longer, it causes more over-heating effect due to 
the hydrogen in human tissue. Since the team proved that 980nm wavelength was 
strong enough to penetrate 12mm of tissue, further study needs to be proceeded in 
order to find out the smaller wavelength laser such as 800nm or 750nm wavelength. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
MQP Report                                                                                                                                      57 
 
References 
 
o American Cancer Society, "Cancer Facts & Figures 2013."  4 Sept. 2012a. Web. 26 Sept. 
2013. <http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-
figures-201>. 
o American Cancer Society, "Learning About New Cancer Treatments." 4 Sept. 2012b. Web. 26 
Sept. 2013. 
<http://www.cancer.org/treatment/treatmentsandsideeffects/complementaryandalternativeme
dicine/learningaboutnewcancertreatments/learning-about-new-ways-to-treat-cancer-toc>. 
o Auzel, F. (2004). Upconversion and anti-Stokes processes with f and d ions in solids. 
Chemical reviews, 104(1), 139-174. 
o Castano, A. P., Mroz, P., & Hamblin, M. R. (2006). Photodynamic therapy and anti-tumour 
immunity. Nature Reviews Cancer, 6(7), 535-545. 
o Chen, G., Shen, J., Ohulchanskyy, T. Y., Patel, N. J., Kutikov, A., Li, Z., ... & Han, G. (2012). 
(α-NaYbF4: Tm3+)/CaF2 Core/Shell Nanoparticles with Efficient Near-Infrared to Near-
Infrared Upconversion for High-Contrast Deep Tissue Bioimaging. ACS nano, 6(9), 8280-
8287. 
o Chen, Xueyuan, Yongsheng Liu, and Datao Tu. "Lanthanide-Doped Luminescent 
Nanomaterials." (2014). 
o Carling, C. J., Nourmohammadian, F., Boyer, J. C., & Branda, N. R. (2010). Remote‐Control 
Photorelease of Caged Compounds Using Near‐Infrared Light and Upconverting 
Nanoparticles. Angewandte Chemie International Edition,49(22), 3782-3785.  
o Dougherty, T. J., Gomer, C. J., Henderson, B. W., Jori, G., Kessel, D., Korbelik, M., ... & 
Peng, Q. (1998). Photodynamic therapy. Journal of the National Cancer Institute, 90(12), 
889-905. 
o Erbium Oxide; MSDS No. 25883 [Online]; Acros Organics N.V.: Fair Lawn, NJ,November 
20, 2008, http://fscimage.fishersci.com/msds/25883.htm (accessed December 2, 2011). 
o Fingar, V. H. (1996). Vascular effects of photodynamic therapy. Journal of clinical laser 
medicine & surgery, 14(5), 323-328. 
o Haase, M., & Schäfer, H. (2011). Upconverting nanoparticles. Angewandte Chemie 
International Edition, 50(26), 5808-5829. 
o Idris, N. M., Gnanasammandhan, M. K., Zhang, J., Ho, P. C., Mahendran, R., & Zhang, Y. 
(2012). In vivo photodynamic therapy using upconversion nanoparticles as remote-controlled 
nanotransducers. Nature Medicine. 
MQP Report                                                                                                                                      58 
 
o Jayakumar, Muthu Kumara Gnanasammandhan, Niagara Muhammad Idris, and Yong Zhang. 
"Remote activation of biomolecules in deep tissues using near-infrared-to-UV upconversion 
nanotransducers." Proceedings of the National Academy of Sciences 109.22 (2012): 8483-
8488. 
o Kalka, K., Merk, H., & Mukhtar, H. (2000). Photodynamic therapy in dermatology. Journal of 
the American Academy of Dermatology, 42(3), 389-413. 
o Liu, Y., Tu, D., Zhu, H., Ma, E., & Chen, X. (2013). Lanthanide-doped luminescent nano-
bioprobes: from fundamentals to biodetection. Nanoscale, 5(4), 1369-1384. 
o Levy, Alison Rose. "The Sky-High Price of Chemotherapy: Why Do Cancer Drugs Cost So 
Much?" TakePart. N.p., 09 May 2013.  
o Mader, H. S., Kele, P., Saleh, S. M., & Wolfbeis, O. S. (2010). Upconverting luminescent 
nanoparticles for use in bioconjugation and bioimaging. Current opinion in chemical 
biology, 14(5), 582-596. 
o MOAN, J., & Peng, Q. (2003). An outline of the hundred-year history of PDT. Anticancer 
research, 23(5A), 3591-3600. 
o Oleinick, N. L., Morris, R. L., & Belichenko, I. (2002). The role of apoptosis in response to 
photodynamic therapy: what, where, why, and how. Photochemical & Photobiological 
Sciences, 1(1), 1-21. 
o Sharman, W. M., Allen, C. M., & van Lier, J. E. (1999). Photodynamic therapeutics: basic 
principles and clinical applications. Drug discovery today, 4(11), 507-517. 
o Shen, J., Chen, G., Vu, A. M., Fan, W., Bilsel, O. S., Chang, C. C., & Han, G. (2013). 
Engineering the Upconversion Nanoparticle Excitation Wavelength: Cascade Sensitization of 
Tri‐doped Upconversion Colloidal Nanoparticles at 800 nm. Advanced Optical Materials. 
o Wang, C., Cheng, L., & Liu, Z. (2013). Upconversion nanoparticles for photodynamic 
therapy and other cancer therapeutics. Theranostics, 3(5), 317. 
o Wang, F., Banerjee, D., Liu, Y., Chen, X., & Liu, X. (2010). Upconversion nanoparticles in 
biological labeling, imaging, and therapy. Analyst, 135(8), 1839-1854. 
o Wang, J., Wang, F., Wang, C., Liu, Z., & Liu, X. (2011). Single‐Band Upconversion Emission 
in Lanthanide‐Doped KMnF3 Nanocrystals. Angewandte Chemie International Edition, 
50(44), 10369-10372. 
o Wilhelm, S., Hirsch, T., Schueucher, E., Mayr, T., & Wolfbeis, O. (2012). Magnetic core-shell 
rare earth doped nanoparticles wih tunable upconversion luminescence for sensor 
applications., Available from Analtyk Chemistry. (WO609-12-1)Retrieved from http://www-
analytik.chemie.uniregensburg.de/wolfbeis/hirsch/Poster/Poster_Europtrode_2012_Magnetic
MQP Report                                                                                                                                      59 
 
_Core-Shell_UCLNPs.pdf Yang, Y., Shao, Q., Deng, R., Wang, C., Teng, X., Cheng, K., ... & 
Xing, B. (2012). In vitro and in vivo uncaging and bioluminescence imaging by using 
photocaged upconversion nanoparticles. Angewandte Chemie International Edition, 51(13), 
3125 3129 
o G. Tian, W. Ren, L. Yan, S. Jian, Z. Gu, L. Zhou, S. Jin, W. Yin, S. Li, Y. Zhao, Small 2013, 9, 
1929. 
o Ytterbium Oxide; MSDS No. 96772 [Online]; Acros Organics N.V.: Fair Lawn, NJ, July 20, 
2009, http://www.jtbaker.com/msds/englishhtml/d7120.htm 
o Z. Huang, Technology in cancer research & treatment 2005, 4, 283. 
o Q. Peng, K. Berg, J. Moan, M. Kongshaug, J. M. Nesland, Photochemistry and Photobiology 
1997, 65, 235. 
o S. Collaud, A. Juzeniene, J. Moan, N. Lange, Current Medicinal Chemistry -Anti-Cancer 
Agents 2004, 4, 301. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
